Quantinno Capital Management LP Acquires 19,281 Shares of Prestige Consumer Healthcare Inc. $PBH

Key Points

• Quantinno Capital Management more than doubled its Prestige Consumer Healthcare stake, acquiring 19,281 shares in the first quarter and bringing its holdings to 36,990 shares valued at approximately $2.19 million. Institutional investors collectively own 99.95% of PBH.
• Analyst sentiment is mixed, with two Buy, two Hold, and two Sell ratings; the consensus rating is Hold with an average price target of $70.75.
• Prestige Consumer Healthcare exceeded quarterly expectations, reporting $0.98 in EPS versus the $0.89 consensus and $265.71 million in revenue, up 6.5% year over year. Shares opened at $52.79, near the lower end of their $42.62–$71.07 one-year range.

Quantinno Capital Management LP grew its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 108.9% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 36,990 shares of the company's stock after buying an additional 19,281 shares during the quarter. Quantinno Capital Management LP owned approximately 0.08% of Prestige Consumer Healthcare worth $2,192,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Norges Bank acquired a new stake in Prestige Consumer Healthcare in the 4th quarter valued at about $36,954,000. Brandes Investment Partners LP lifted its position in shares of Prestige Consumer Healthcare by 93.2% during the fourth quarter. Brandes Investment Partners LP now owns 606,737 shares of the company's stock worth $37,430,000 after purchasing an additional 292,744 shares in the last quarter. Capital Research Global Investors lifted its position in shares of Prestige Consumer Healthcare by 107.9% during the fourth quarter. Capital Research Global Investors now owns 561,497 shares of the company's stock worth $34,639,000 after purchasing an additional 291,425 shares in the last quarter. Squarepoint Ops LLC grew its stake in shares of Prestige Consumer Healthcare by 316.1% during the third quarter. Squarepoint Ops LLC now owns 301,866 shares of the company's stock valued at $18,836,000 after purchasing an additional 229,311 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of Prestige Consumer Healthcare by 28.4% during the first quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company's stock valued at $46,997,000 after purchasing an additional 120,965 shares during the last quarter. 99.95% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

PBH has been the subject of a number of research reports. Zacks Research lowered shares of Prestige Consumer Healthcare from a "hold" rating to a "strong sell" rating in a report on Monday, May 18th. Oppenheimer cut Prestige Consumer Healthcare from an "outperform" rating to a "market perform" rating in a research note on Thursday, May 14th. Weiss Ratings downgraded Prestige Consumer Healthcare from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Thursday, June 25th. Finally, Canaccord Genuity Group decreased their price target on Prestige Consumer Healthcare from $86.00 to $72.00 and set a "buy" rating on the stock in a report on Friday, May 15th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $70.75.

Prestige Consumer Healthcare Price Performance

Prestige Consumer Healthcare stock opened at $52.79 on Tuesday. The company has a current ratio of 3.23, a quick ratio of 1.99 and a debt-to-equity ratio of 1.06. The firm has a market capitalization of $2.50 billion, a P/E ratio of 14.79, a PEG ratio of 1.70 and a beta of 0.34. The business has a 50-day moving average of $48.96 and a 200-day moving average of $55.91. Prestige Consumer Healthcare Inc. has a 1 year low of $42.62 and a 1 year high of $71.07.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.09. The business had revenue of $265.71 million for the quarter, compared to analyst estimates of $253.02 million. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. Prestige Consumer Healthcare's quarterly revenue was up 6.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.90 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. On average, equities analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.6 EPS for the current year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.

Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source